Scholars@Duke
Donald Patrick McDonnell

Donald Patrick McDonnell

Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine
Pharmacology & Cancer Biology
donald.mcdonnell@duke.edu
Box 103057, Durham, NC 27710
2138 MSRB3, 3 Genome Court, Durham, NC 27710

Scholarly Works - Other

Supplementary Figure S1 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Fig. S1. A) UMAP visualization of scRNA-seq data colored by patient identity. B) UMAP visualization of scRNA-seq data colored by timepoint (T1 = pre-abemaciclib and ET, T2 = post-abemaciclib and ET). C) Dot plot of proportion ... Full text Cite

Supplementary Figure S10 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplemental Figure 10. Kaplan-Meier plots showing association of (A) myeloid cluster gene signatures and (B) relative cell type deconvolution fraction with survival in metastatic patients in the AURORA (<i>n</i> = 34 patients) ... Full text Cite

Supplementary Figure S5 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Fig. S5. Line plot depicting change in proportion of lymphoid cells identified as cluster 6: CTLA4 Tregs for each patient from T1 to T2.</p> ... Full text Cite

Supplementary Figure S9 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Fig. S9. A) Heatmap of top 20 differentially expressed genes between myeloid cluster 0: APOC1 TAMs, myeloid cluster 5: TREM2 TAMs, and cluster 7: APOC2 TAMs. B) Heatmap of top 20 enriched pathways derived from genes identifie ... Full text Cite

Supplementary Figure S3 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Fig. S3. A) UMAP visualization of G1/S CDKs, CDK4, CDK6, and CDK2. B) C) Heatmap depicting differential expression of CDK4/6 target genes and proliferation markers in each cluster grouped by response. Color indicates average ... Full text Cite

Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Fig. S2. A) UMAP visualization of lymphoid marker genes. B) Relative proportions of lymphoid clusters per patient per timepoint per metastasis site. C) Relative proportions of lymphoid clusters per patient per timepoint per r ... Full text Cite

Supplementary Figure S7 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Fig. S7. A) UMAP visualization of G1/S CDKs, CDK4, CDK6, and CDK2. B) C) Heatmap depicting differential expression of CDK4/6 target genes and proliferation markers in each cluster grouped by response. Color indicates average ... Full text Cite

Supplementary Figure S6 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Fig. S6. A) UMAP visualization of myeloid cell type markers for macrophages (CD68), M2-like macrophages (CD163), antigen-presenting cells (HLA-DRA), monocytes (CD14), dendritic cells (CD1C), and mast cells (KIT). B) Relative ... Full text Cite

Supplementary Figure S4 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Fig. S4. A) Box plot of IFNG expression at T1 and T2 for each T cell cluster grouped by response. Median expression is indicated by green line. Statistical significance determined by two-way ANOVA with post-hoc Tukey-HSD test ... Full text Cite

Supplementary Tables S2-S12 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Table S2. Patient characteristics and number of cells analyzed. Supplementary Table S3. Marker genes for each cluster Supplementary Table S4. ANOVA with Tukey HSD multiple test correction results for cell type population size ... Full text Cite

Supplementary Figure S8 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <p>Supplementary Fig. S8. Heatmap depicting gene set enrichment results identified from genes that were differentially expressed between T1 and T2 for each myeloid cluster in each response group. Color indicates normalized enrichment score wh ... Full text Cite

Data from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

Other · August 3, 2026 <div>Abstract Purpose:<p>In advanced estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative breast cancer, the combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy ... Full text Cite

Supplementary Table S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Table S5 shows Cell proliferation IC50 and maximum inhibition (Emax) in parental and ERY537S (heterozygous) after different ER ligands treatment.</p> ... Full text Cite

Data from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <div>Abstract<p>Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER)–positive, HER2-negative (ER<sup>+</sup>/HER2<sup>−</sup>) breast cancer; however, <i>de novo</i> ... Full text Cite

Supplementary Figure S2 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S2 shows ZN-c5 demonstrates minor agonist effect on uterine tissue A. Uterine wet weight change in juvenile rats treated with different doses of ZN-c5. B. H&E staining on uterine tissues after ZN-c5 treatment. Imag ... Full text Cite

Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S5 shows ZN-c5 activity in ERY537S tumors. A. Key ER downstream targets expression by qPCR in WT or ERY537S heterozygous cells. B. ER downstream target GREB expression by qPCR in WT or ERY537S heterozygous cells after ... Full text Cite

Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S1 shows ZN-c5 is a novel SERD that inhibits growth of ER + tumors in vitro and in vivo A. ERα degradation curve after ZN-c5 treatment and DC50 (concentration at 50% degradation) determination for Figure 1B top; B. Top ... Full text Cite

Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S4 shows Combination of ZN-c5 and palbociclib further arrests the cells at G1 phase A. Relative ER level to DMSO after normalized to β-actin control for Figure 4B. B. MCF-7 cells were treated with 500nM of palbociclib ... Full text Cite

Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Table S3 shows The effect of ZN-c5 and tamoxifen on E2-induced genes</p> ... Full text Cite

Supplementary Table S2 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Table S2 shows ZN-c5 human nuclear receptor profiling and estrogen receptor binding affinity</p> ... Full text Cite

Supplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Table S4 shows The effect of ZN-c5 and tamoxifen on E2-suppressed genes</p> ... Full text Cite

Supplementary Figure S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other · April 2, 2026 <p>Supplementary Figure S3 demonstrates ZN-c5 protects bone loss in ovariectomized mice A. Progesterone level in serum was measured after Ovariectomy (OVX) or sham surgery to confirm the success of ovariectomy. B and C. BMD in femur and tibia ... Full text Cite

Data from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · November 24, 2025 <div>Abstract<p>Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains hi ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · November 24, 2025 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Data from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <div>Abstract<p>Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains h ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Supplementary Table S2 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Other · March 15, 2024 <p>Association of CTC HOXB13 expression with overall survival, univariate and multivariate analysis including adjustment for JHU CTC AR-V7 status</p> ... Full text Cite

Supplementary Table S2 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Other · March 15, 2024 <p>Association of CTC HOXB13 expression with overall survival, univariate and multivariate analysis including adjustment for JHU CTC AR-V7 status</p> ... Full text Cite

Data from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Other · March 15, 2024 <div>AbstractPurpose:<p>HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) HOXB13 expression with outcomes in men with mCRPC treated ... Full text Cite

Data from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Other · March 15, 2024 <div>AbstractPurpose:<p>HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) HOXB13 expression with outcomes in men with mCRPC treated ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Data from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <div>Abstract<p>Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains hi ... Full text Cite

Data from Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells

Other · April 4, 2023 <div>Abstract<p>Calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) is a key regulator of energy homeostasis in several cell types. Expression of this enzyme in tumor cells promotes proliferation and migration, and expression ... Full text Cite

Data from Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells

Other · April 4, 2023 <div>Abstract<p>Calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) is a key regulator of energy homeostasis in several cell types. Expression of this enzyme in tumor cells promotes proliferation and migration, and expression ... Full text Cite